JP7746280B2 - 新規脂質及びそれらのナノ粒子組成物 - Google Patents

新規脂質及びそれらのナノ粒子組成物

Info

Publication number
JP7746280B2
JP7746280B2 JP2022558110A JP2022558110A JP7746280B2 JP 7746280 B2 JP7746280 B2 JP 7746280B2 JP 2022558110 A JP2022558110 A JP 2022558110A JP 2022558110 A JP2022558110 A JP 2022558110A JP 7746280 B2 JP7746280 B2 JP 7746280B2
Authority
JP
Japan
Prior art keywords
lipid
aspects
cedna
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518985A5 (cg-RX-API-DMAC7.html
JP2023518985A (ja
Inventor
マシュー ジー. スタントン,
バート ノルティング,
Original Assignee
ジェネレーション バイオ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネレーション バイオ カンパニー filed Critical ジェネレーション バイオ カンパニー
Publication of JP2023518985A publication Critical patent/JP2023518985A/ja
Publication of JP2023518985A5 publication Critical patent/JP2023518985A5/ja
Priority to JP2025154013A priority Critical patent/JP2025181861A/ja
Application granted granted Critical
Publication of JP7746280B2 publication Critical patent/JP7746280B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022558110A 2020-03-27 2021-03-26 新規脂質及びそれらのナノ粒子組成物 Active JP7746280B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025154013A JP2025181861A (ja) 2020-03-27 2025-09-17 新規脂質及びそれらのナノ粒子組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000990P 2020-03-27 2020-03-27
US63/000,990 2020-03-27
PCT/US2021/024413 WO2021195529A2 (en) 2020-03-27 2021-03-26 Novel lipids and nanoparticle compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025154013A Division JP2025181861A (ja) 2020-03-27 2025-09-17 新規脂質及びそれらのナノ粒子組成物

Publications (3)

Publication Number Publication Date
JP2023518985A JP2023518985A (ja) 2023-05-09
JP2023518985A5 JP2023518985A5 (cg-RX-API-DMAC7.html) 2024-04-04
JP7746280B2 true JP7746280B2 (ja) 2025-09-30

Family

ID=77890624

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558110A Active JP7746280B2 (ja) 2020-03-27 2021-03-26 新規脂質及びそれらのナノ粒子組成物
JP2025154013A Pending JP2025181861A (ja) 2020-03-27 2025-09-17 新規脂質及びそれらのナノ粒子組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025154013A Pending JP2025181861A (ja) 2020-03-27 2025-09-17 新規脂質及びそれらのナノ粒子組成物

Country Status (11)

Country Link
US (3) US12534435B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125821A4 (cg-RX-API-DMAC7.html)
JP (2) JP7746280B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220160647A (cg-RX-API-DMAC7.html)
CN (1) CN115916163A (cg-RX-API-DMAC7.html)
AU (1) AU2021241696B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019369A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173126A1 (cg-RX-API-DMAC7.html)
IL (1) IL296763B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011988A (cg-RX-API-DMAC7.html)
WO (1) WO2021195529A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
US12534435B2 (en) * 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
AU2021307952A1 (en) * 2020-07-17 2023-03-02 Generation Bio Co. Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
CN118251212A (zh) * 2021-09-30 2024-06-25 日油株式会社 用于将核酸递送至淋巴管内皮细胞的脂质纳米颗粒
WO2023121964A1 (en) * 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
JPWO2023190164A1 (cg-RX-API-DMAC7.html) * 2022-03-28 2023-10-05
CA3247022A1 (en) 2022-03-28 2025-07-08 National University Corporation Chiba University METHOD FOR PRODUCING LIPID NANOPARTICLES ENCAPSULATED IN A NUCLEIC ACID, METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO A CELL OR A TARGET CELL
WO2023190175A1 (ja) 2022-03-28 2023-10-05 日油株式会社 末梢血単核細胞へ核酸を送達するための脂質ナノ粒子およびこれを用いて末梢血単核細胞へ核酸を送達する方法
JPWO2023190176A1 (cg-RX-API-DMAC7.html) 2022-03-28 2023-10-05
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
KR20250038709A (ko) 2022-07-15 2025-03-19 니치유 가부시키가이샤 지질 나노입자 및 이의 제조 방법, 핵산-캡슐화 지질 나노입자 및 이의 제조 방법, 및 핵산-캡슐화 지질 나노입자를 사용하여 생체에서 획득 면역을 유도하는 방법
KR20250037535A (ko) 2022-07-15 2025-03-17 니치유 가부시키가이샤 핵산-로딩된 지질 나노입자의 동결건조 조성물
WO2024192528A1 (en) * 2023-03-22 2024-09-26 Nanovation Therapeutics Inc. Ionizable anionic lipids
WO2024203660A1 (ja) 2023-03-29 2024-10-03 国立大学法人東北大学 核酸内封脂質ナノ粒子の製造方法
CN116082184B (zh) * 2023-04-12 2023-06-30 山东大学 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025043146A2 (en) * 2023-08-24 2025-02-27 Molecular Axiom Inc. Lipid nanoparticle compositions and methods of using same
CN121909024A (zh) 2023-09-22 2026-04-21 国立大学法人东北大学 包封有核酸的配体修饰脂质纳米颗粒的制造方法
US20260234104A1 (en) * 2023-12-15 2026-08-13 Xiamen Sinopeg Biotech Co., Ltd. Degradable cationic lipid containing a disulfide bond and applications thereof
WO2025150516A1 (ja) 2024-01-12 2025-07-17 日油株式会社 核酸内封脂質ナノ粒子を含む凍結組成物
CN117964577B (zh) * 2024-03-29 2024-06-21 天津全和诚生物技术有限公司 阳离子脂质化合物、其制备方法、包含其的组合物及应用
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026070952A1 (ja) * 2024-09-27 2026-04-02 日油株式会社 ジスルフィド結合を有する化合物およびその製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335157A1 (en) 2011-11-18 2014-11-13 Nof Corporation Cationic lipid having improved intracellular kinetics
WO2019188867A1 (ja) 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
EP2310440A4 (en) 2008-07-10 2013-06-05 Serina Therapeutics Inc POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
WO2012046265A1 (ja) * 2010-10-05 2012-04-12 トヨタ自動車株式会社 推定装置および推定方法
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9035039B2 (en) * 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
TWI595885B (zh) 2012-05-02 2017-08-21 喜納製藥公司 包含四galnac之新穎結合物及傳送寡核苷酸之方法
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2017084987A1 (en) 2015-11-16 2017-05-26 F. Hoffmann-La Roche Ag GalNAc CLUSTER PHOSPHORAMIDITE
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL261524B2 (en) 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
JP2019151589A (ja) * 2018-03-02 2019-09-12 国立大学法人北海道大学 脂質ナノ粒子
JP7075256B2 (ja) * 2018-03-28 2022-05-25 三菱重工業株式会社 配管の余寿命評価方法
CN114929205B (zh) 2019-09-06 2024-09-03 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
US12534435B2 (en) 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
AU2021307952A1 (en) * 2020-07-17 2023-03-02 Generation Bio Co. Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335157A1 (en) 2011-11-18 2014-11-13 Nof Corporation Cationic lipid having improved intracellular kinetics
WO2019188867A1 (ja) 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質

Also Published As

Publication number Publication date
IL296763A (en) 2022-11-01
EP4125821A2 (en) 2023-02-08
WO2021195529A3 (en) 2021-11-18
WO2021195529A2 (en) 2021-09-30
KR20220160647A (ko) 2022-12-06
JP2025181861A (ja) 2025-12-11
JP2023518985A (ja) 2023-05-09
CN115916163A (zh) 2023-04-04
IL296763B1 (en) 2025-12-01
IL296763B2 (en) 2026-04-01
BR112022019369A2 (pt) 2022-12-13
MX2022011988A (es) 2023-01-04
US20250361208A1 (en) 2025-11-27
US20240294474A1 (en) 2024-09-05
CA3173126A1 (en) 2021-09-30
EP4125821A4 (en) 2024-06-26
AU2021241696B2 (en) 2026-08-06
US12252470B2 (en) 2025-03-18
US12534435B2 (en) 2026-01-27
AU2021241696A1 (en) 2022-12-01
US20230159459A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
US12252470B2 (en) Lipids and nanoparticle compositions thereof
JP7700101B2 (ja) 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
JP2026074198A (ja) ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤
US20220370357A1 (en) Ionizable lipids and nanoparticle compositions thereof
US20240293574A1 (en) Cationic lipids and compositions thereof
JP7863051B2 (ja) 新規脂質及びそれらのナノ粒子組成物
JP2024517644A (ja) カチオン性脂質及びその組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250917

R150 Certificate of patent or registration of utility model

Ref document number: 7746280

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150